The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma—continues to rise; however, treatment options remain limited. Targeted therapies, including Herceptin (Roche / Genentech / Chugai [for HER2-positive patients only]) and Cyramza (Eli Lilly), have been approved exclusively for gastric and GEJ adenocarcinoma patients across the major markets. Additional agents are also approved for later-line treatments in certain geographies, such as Keytruda (Merck & Co.), Opdivo (Bristol-Myers Squibb), and Lonsurf (Taiho). A plethora of agents including immunotherapies, vaccines, and a variety of targeted therapies are vying for approval in underserved patient segments, such as resectable disease or the first-line metastatic setting.

Questions Answered

  • How do current treatment practices differ among esophageal, gastric, and GEJ cancer patients? Do these practices differ by geography, and which populations provide the greatest drug-treatment opportunities?
  • What are interviewed experts’ insights on the use of currently approved agents? What clinical needs remain unfulfilled, and on what opportunities can developers capitalize?
  • Which drugs in late-phase development are poised to change the treatment landscape for gastroesophageal cancer? How are these agents being assessed, and how will they impact the gastroesophageal cancer market?
  • What are the key market drivers and constraints in the gastroesophageal market, and how will the market evolve over the forecast period?

Content Highlights

Geographies: United States, EU5, Japan.

Primary research: 23 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research.

Epidemiology: Diagnosed and recurrent incidence of gastroesophageal cancer by country, segmented by HER2 status, histology, stage I-IV, and line of therapy.

Forecast: 10-year, annualized, drug-level sales and patient share of key gastroesophageal cancer therapies through 2028, segmented by brands / generics and market-relevant drug treatable populations.

Emerging therapies: Phase III: 9 drugs; Phase I / II: ~30 drugs.

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Related Reports

Gastroesophageal Cancer - Landscape & Forecast - Disease Landscape & Forecast

The incidence of gastroesophageal cancer—encompassing gastric cancer, esophageal cancer, and gastroesophageal junction (GEJ) adenocarcinoma&mdas...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

In this project, comissioned by Janssen in December, 2018, we have packaged our published estimates on the epidemiology of CLL - drug treated population across all the countries in Latin Ameri...

View Details

Gastroesophageal Cancer - Geographic Focus: China - Gastric Cancer - China In-Depth (China)

China has the highest incidence of gastric and GEJ adenocarcinoma globally, and therapeutic options are limited. Only three targeted agents are approved to treat this indication—Roche’s...

View Details

Gastroesophageal Cancer - Unmet Need - Detailed, Expanded Analysis (US & EU) Previously Treated Metastatic Gastric And Gastroesophageal Junction (GEJ) Adenocarcinoma

While the incidence of gastric and GEJ adenocarcinoma continues to rise, efficacious treatment options, especially in the previously treated metastati...

View Details